ZACHARY GIBSON: Open Payments
NPI 1619566833 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$267 in 14 payments from 11 companies in 2025. Trend: 2023 $701 · 2024 $332 · 2025 $267
Food & beverage: $267
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $64 |
| Novo Nordisk Inc | 2 | $36 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Amgen Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: VRAYLAR, Wegovy, LEQVIO, Auvelity, OTEZLA, Qelbree, Kerendia, GARDASIL 9.
Industry payments across UT — which companies pay providers there.
